Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population (Q36143045)

12 August 2017

0 references

Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population (English)

1 reference

amyotrophic lateral sclerosis

12 August 2017

1 reference

A Czaplinski

1

1 reference

12 August 2017

A A Yen

series ordinal

2

1 reference

12 August 2017

S H Appel

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Journal of Neurology, Neurosurgery and Psychiatry

12 August 2017

1 reference

12 August 2017

77

1 reference

12 August 2017

3

1 reference

12 August 2017

390-392

1 reference

Disease progression in amyotrophic lateral sclerosis: predictors of survival

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Respiratory dysfunction in amyotrophic lateral sclerosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Amyotrophic lateral sclerosis. Its natural history

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Effects of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

The ALSFRSr predicts survival time in an ALS clinic population

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Functional outcome measures as clinical trial endpoints in ALS.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Design using historical controls.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Early symptom progression rate is related to ALS outcome: a prospective population-based study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Bipap improves survival and rate of pulmonary function decline in patients with ALS.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Prognosis of amyotrophic lateral sclerosis and the effect of referral selection.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

The natural history of amyotrophic lateral sclerosis.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

Natural history of amyotrophic lateral sclerosis in a database population Validation of a scoring system and a model for survival prediction

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077717

A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients

23 September 2018

1 reference

12 December 2020

A rating scale for amyotrophic lateral sclerosis: description and preliminary experience

1 reference

12 December 2020

Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Rate of deterioration

1 reference

12 December 2020

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

12 December 2020

Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group

1 reference

12 December 2020

Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1136/JNNP.2005.072660

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

16484652

1 reference